Literature DB >> 25548141

Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study.

Motohiro Shimizu1, Satoshi Hoshide2, Joji Ishikawa2, Yuichiro Yano2, Kazuo Eguchi2, Kazuomi Kario3.   

Abstract

BACKGROUND: Some previous studies have shown that central blood pressure (BP) is more closely related to cardiovascular risks than brachial BP. This study compared the correlations between asymptomatic organ damages and each of central BP, brachial clinic BP, and home BP during antihypertensive treatment.
METHODS: In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which compared bedtime or awakening dosing of candesartan (+diuretics as needed) among subjects with home systolic BP (SBP) higher than 135 mm Hg, we evaluated 180 hypertensive patients who successfully underwent pulse wave analysis by HEM-9000AI and measured their urinary albumin/creatinine ratio (UACR) and left ventricular mass index (LVMI) (n = 144) at baseline and after 6 months of treatment.
RESULTS: During antihypertensive treatment, significant reductions were found in central SBP, UACR, and LVMI (all P < 0.001). Multiple regression analyses showed that the decrease in central SBP was associated with those of log-transformed UACR (β = 0.24, P < 0.01) and LVMI (β = 0.23, P = 0.04), independently of the decrease in both clinic and home SBP. The goodness-of-fit of the association between the reduction in SBP and the UACR (P < 0.01) or LVMI (P = 0.04) was improved by adding central SBP to the SBP measurement.
CONCLUSION: These findings suggest that the change in central BP could be an important therapeutic target during antihypertensive treatment, in addition to peripheral clinic and home BP. © American Journal of Hypertension, Ltd 2014. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  angiotensin receptor blockade; antihypertensive treatment; blood pressure; central blood pressure; home blood pressure; hypertension; left ventricular hypertrophy; microalbuminuria.

Mesh:

Substances:

Year:  2014        PMID: 25548141     DOI: 10.1093/ajh/hpu250

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  7 in total

Review 1.  The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.

Authors:  Kazuomi Kario
Journal:  Curr Cardiol Rep       Date:  2018-01-27       Impact factor: 2.931

Review 2.  BP Measurement Techniques: What They Mean for Patients with Kidney Disease.

Authors:  George Thomas; Paul E Drawz
Journal:  Clin J Am Soc Nephrol       Date:  2018-02-26       Impact factor: 8.237

3.  Could arterial stiffness be early reversible target organ damage test in childhood hypertension?

Authors:  Duygu Övünç Hacıhamdioğlu; Özben Ceylan; Aytül Hande Yardımcı
Journal:  Anatol J Cardiol       Date:  2021-07       Impact factor: 1.596

4.  Chlorthalidone Plus Amiloride Reduces the Central Systolic Blood Pressure in Stage 1 Hypertension Patients.

Authors:  Leticia Aparecida Barufi Fernandes; Elizabeth do Espirito Santo Cestario; Luciana Neves Cosenso-Martin; Jose Fernando Vilela-Martin; Juan Carlos Yugar-Toledo; Flavio Danni Fuchs
Journal:  Cardiol Res       Date:  2016-12-31

5.  Central systolic blood pressure and central pulse pressure predict left ventricular hypertrophy in hypertensive children.

Authors:  Mieczysław Litwin; Łukasz Obrycki; Anna Niemirska; Jędrzej Sarnecki; Zbigniew Kułaga
Journal:  Pediatr Nephrol       Date:  2018-11-13       Impact factor: 3.714

6.  Do thiazide diuretics reduce central systolic blood pressure in hypertension?

Authors:  Lara B T Yugar; Beatriz Moreno; Heitor Moreno; José F Vilela-Martin; Juan C Yugar-Toledo
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-11-06       Impact factor: 3.738

7.  Oscillometric central blood pressure and central systolic loading in stroke patients: Short-term reproducibility and effects of posture and fasting state.

Authors:  Andrew Mitchelmore; Lee Stoner; Danielle Lambrick; Lucy Sykes; Charlotte Eglinton; Simon Jobson; James Faulkner
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.